Featured Press Releases

Stealth BioTherapeutics announces an FDA advisory committee meeting to review Elamipretide for Barth syndrome treatment

Stealth BioTherapeutics announces an FDA advisory committee meeting to review Elamipretide for Barth syndrome treatment

Galmed releases Phase 3 Aramchol results in Hepatology.

Galmed releases Phase 3 Aramchol results in Hepatology.

  • 26 Sep 2024

Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company for liver, metabolic and...

AusperBio

AusperBio's AHB-137 Receives Breakthrough Therapy Designation for Chronic Hepatitis B Treatment

GC Biopharma and Novelty Nobility sign an R&D agreement to develop therapies for geographic atrophy

GC Biopharma and Novelty Nobility sign an R&D agreement to develop therapies for geographic atrophy

Secretome Therapeutics

Secretome Therapeutics' STM-01, a neonatal cardiac progenitor cell therapy for HFpEF, receives FDA Fast Track designation

Fresenius Kabi Launches Calcitonin Salmon Injection, USP Synthetic

Fresenius Kabi Launches Calcitonin Salmon Injection, USP Synthetic

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

  • P-Cure
  • 17 Feb 2026
To strengthen global AI, data strategy, evidence synthesis, and economic modelling capabilities, Precision AQ expands its senior leadership team

To strengthen global AI, data strategy, evidence synthesis, and economic modelling capabilities, Precision AQ expands its senior leadership team

  • Precision AQ
  • 17 Feb 2026
New ECCO data demonstrate that subcutaneous infliximab (Remsima™ SC) recaptures and maintains disease control following a drug holiday

New ECCO data demonstrate that subcutaneous infliximab (Remsima™ SC) recaptures and maintains disease control following a drug holiday

  • Celltrion
  • 16 Feb 2026
Breakthrough in Zika Virus Drug Discovery Reported by IRBM

Breakthrough in Zika Virus Drug Discovery Reported by IRBM

  • IRBM
  • 14 Feb 2026
A Breakthrough Study Confirms HYD LLC

A Breakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression.

  • HYD LLC
  • 13 Feb 2026
FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

  • KORU Medical Systems, Inc.
  • 02 Feb 2026
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.